Tongjitang Establishes Special Committee to Evaluate Buyout Proposal

SHENZHEN, China, April 12 TongjitangChinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), aleading specialty pharmaceutical company focusing on the development,manufacturing, marketing and selling of modernized traditional Chinesemedicine in China, today announced that it has established a special committee(the "special committee") to evaluate the proposal presented on April 8, 2010by Hanmax Investment Ltd. and Fosun Industrial Co., Ltd. If the proposal isaccepted, Hanmax Investment Ltd. and Fosun Industrial Co., Ltd. will acquireall of the outstanding ordinary shares of the Company (including ordinaryshares outstanding in the form of American Depositary Shares) in a mergertransaction under Cayman Islands law that would result in the Company becominga privately-held company.

The special committee is composed of the Company's three independentdirectors: Mr. Yongcun Chen, Dr. Harry K. Genant, and Mr. David R. White. Thespecial committee was directed to review the proposal, and intends to providean assessment of the proposal to the Company.

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiariesTongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores,Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and AnhuiJingfang, is a vertically integrated specialty pharmaceutical company focusedon the development, manufacturing, marketing and selling of modernizedtraditional Chinese medicine in China. Tongjitang's principal executiveoffices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditionalChinese medicine for the treatment of osteoporosis in China as measured bysales in Renminbi. In addition to Xianling Gubao, the Company manufactures andmarkets 36 other modernized traditional Chinese medicine products and 37western medicines. Please visit http://www.tongjitang.com for more information.For more information, please contact: ICR, Inc. Ashley M. Ammon or Christine Duan Tel: +1-203-682-8200 (Investor Relations)

SOURCE Tongjitang Chinese Medicines Company

Latest Press Release on Corporate News

KPJ Pasir Gudang Specialist Hospital Partners with NetSfere for Secure and Compliant Messaging

CHICAGO, March 26, 2024 (GLOBE NEWSWIRE) -- NetSfere , a global provider of next-generation secure and compliant messaging and mobility solutions, today announces that KPJ Pasir Gud...

Philips convenes the Annual General Meeting of Shareholders 2024

March 22, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced it has convened the Annual General Meeting of Shareholders (AGM) 2024 and pu...

Amlan International Forges Strategic Partnership with Grupo Profil as its Newest Latin American Distributor, Amplifying Access to Innovative Gut Health Solutions for Protein Producers

CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amlan ® International, the animal health division of Oil-Dri ® Corporation of America, is excited to announce its partnership with Grupo P...

Impulse Dynamics Completes $136M Financing Round

Marlton, NJ, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to an...

Global Healthcare E-commerce Market to Accrue $1038.17 Billion by 2030, Registering a Robust 19.93% CAGR, Propelled by Rising Adoption of Online Healthcare Solutions, States Kings Research

DUBAI , UAE , Feb. 13, 2024 /PRNewswire/ -- According to a recent Kings Research study, the global Healthcare E-c ommerce Market was valued at USD 244.99 billion in 2022...